Adempas is a medicine used to treat pulmonary hypertension (high blood pressure in the blood vessels of the lungs). It is used in the following types of pulmonary hypertension: - Chronic thromboembolic pulmonary hypertension (CTEPH, where the blood vessels of the lungs are blocked or narrowed with blood clots). Adempas is used to treat adults with CTEPH who cannot have surgery, or in whom CTEPH remains or returns after surgery. - Pulmonary arterial hypertension (PAH, where the walls of the blood vessels of the lungs are thickened and the vessels become narrowed) in adults and in children above 6 years of age. In adults with PAH, Adempas can be used on its own or in combination with other medicines for PAH called endothelin receptor antagonists whereas in children it is used with endothelin receptor antagonists. Adempas is used in patients with functional class II to III CTEPH or PAH. The ‘class’ reflects the seriousness of the disease: class II involves a slight limitation of physical activity while class III involves a marked limitation of physical activity. Adempas contains the active substance riociguat.
Therapeutic Indication
### Therapeutic indication **Chronic thromboembolic pulmonary hypertension (CTEPH)** Adempas is indicated for the treatment of adult patients with WHO Functional Class (FC) II to III with - inoperable CTEPH, - persistent or recurrent CTEPH after surgical treatment, - to improve exercise capacity. **Pulmonary arterial hypertension (PAH)** **Adults** Adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity. Efficacy has been shown in a PAH population including aetiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease. **Paediatrics** Adempas is indicated for the treatment of PAH in paediatric patients aged less than 18 years of age and body weight ? 50 kg with WHO Functional Class (FC) II to III in combination with endothelin receptor antagonists.
Therapeutic Area (MeSH)
ATC Code
C02KX05
ATC Item
riociguat
Pharmacotherapeutic Group
Antihypertensives for pulmonary arterial hypertension
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| riociguat | N/A | 利奥西呱 |
EMA Name
Adempas
Medicine Name
Adempas
Aliases
N/A
